New injection after liver ablation aims to stop colorectal cancer in its tracks
NCT ID NCT07321847
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests if a new drug called IP-001, injected into the liver after standard heat ablation, can prevent colorectal cancer from coming back in people whose cancer has spread only to the liver. About 717 adults will be randomly assigned to receive ablation alone or ablation plus a low or high dose of IP-001. The goal is to see if the injection boosts the immune system to destroy any remaining cancer cells and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Conditions
Explore the condition pages connected to this study.